|
Infiltrating duct carcinoma of female breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Metastasis is highly dependent upon the suppression of anoikis and the role of C/EBPβ and LIP in this anchorage-independent, survival process is currently not known in mammary epithelial cells.
|
21854628 |
2011 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ATX gene was found to be overexpressed in some HCC and correlated with HCC development and metastases.
|
11593532 |
1999 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
ATX gene was found to be overexpressed in some HCC and correlated with HCC development and metastases.
|
11593532 |
1999 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
ATX gene was found to be overexpressed in some HCC and correlated with HCC development and metastases.
|
11593532 |
1999 |
|
Glioblastoma Multiforme
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ATX generates lysophosphatidic acid (LPA), which signals through LPA receptors expressed by GBM as well as in astrocytes, oligodendrocytes (ODC) and microglia; their activation manifest cell specific effects.
|
17928955 |
2008 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ATX-101 also increased multiple myeloma cells' sensitivity against melphalan, a DNA damaging agent commonly used for treatment of multiple myeloma.
|
23936203 |
2013 |
|
Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ATX and its catalytic product, lysophosphatidic acid (LPA), regulated the signaling pathways and cell motility of RCC in vitro.
|
24122794 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ATX and its catalytic product, lysophosphatidic acid (LPA), regulated the signaling pathways and cell motility of RCC in vitro.
|
24122794 |
2013 |
|
Refractory Cytopenia of Childhood
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ATX and its catalytic product, lysophosphatidic acid (LPA), regulated the signaling pathways and cell motility of RCC in vitro.
|
24122794 |
2013 |
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target.(Hepatology 2017;65:1369-1383).
|
27981605 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target.(Hepatology 2017;65:1369-1383).
|
27981605 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target.(Hepatology 2017;65:1369-1383).
|
27981605 |
2017 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
ATX has additional abilities such as antagonistic effects on the N-methyl-Daspartate receptors (NMDARs) and benefit effects in some animal models of neurological disorders.
|
28356001 |
2017 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
ATX pretreatment reduced ischemia-induced hyperactivity and protected CA1 pyramidal neurons from ischemia.
|
28356001 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
SMG-1 inhibition by miR-192/-215 causes epithelial-mesenchymal transition in gastric carcinogenesis via activation of Wnt signaling.
|
29239144 |
2018 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
ATX and LPA have been implicated in key (patho)physiologic processes, including embryonic development, lymphocyte homing, inflammation, and cancer progression.
|
30481488 |
2019 |
|
Chronic colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ATX blockade was able to relieve symptoms and inflammatory response of DSS-induced chronic colitis.
|
31102124 |
2019 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.
|
31469826 |
2019 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.
|
31469826 |
2019 |
|
Fibrosis, Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Accordingly, it has been hypothesized that ATX promoter methylation and ATX expression in peripheral blood may serve as possible biomarkers reflecting the progression of liver fibrosis in postoperative BA.
|
28052132 |
2017 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Altered expression of SMG-1 contributes to human carcinogenesis and cancer progression.
|
25760059 |
2015 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Altered expression of SMG-1 contributes to human carcinogenesis and cancer progression.
|
25760059 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the inter-patient variability was large, we found that LIP, the isoform of C/EBPbeta known to inhibit transcription, was expressed at higher levels in Duke's stage B tumors compared with Duke's stage A, whereas Duke's C tumors had the lowest LIP expression.
|
10760820 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An important player in the DDR, SMG-1 (suppressor with morphogenetic effect on genitalia), is a potential tumor suppressor and may therefore be deregulated in cancer.
|
22247495 |
2012 |